Every week, people across Ireland ask the same question: "Is Mounjaro covered by the medical card?" Right now the honest answer is no — but 2026 is the year that could genuinely change, and the decision process is further along than most people realise.
In June 2026, the head of Ireland's drug-pricing watchdog said his understanding was that a "significant price reduction" had been offered on Mounjaro — and that it may now be judged cost-effective for State funding. Here's exactly where the decision stands, who might qualify, and what your options are today.
The short answer: not covered yet — but the decision is live
As of July 2026, Mounjaro (tirzepatide) is not reimbursed by the HSE for weight management. You cannot get it free on a medical card, and it doesn't count towards the Drug Payment Scheme cap. The same is true of Wegovy.
But this isn't a frozen "no". Eli Lilly applied for HSE reimbursement back in January 2024, the pharmacoeconomic review is complete, and commercial price negotiations are actively underway. The remaining steps are a recommendation to the HSE Drugs Group and a final call by the HSE's leadership.
What the State actually covers today
Only one weight-loss injection is currently funded by the State: Saxenda (liraglutide) — and only under a strict Managed Access Protocol. To qualify, you generally need a BMI of 35 or higher plus prediabetes and a high risk of cardiovascular disease.
Even then, the funding is conditional: if you haven't lost at least 5% of your body weight after 12 weeks on the full dose, treatment support stops. Coverage under the scheme can last up to two years. Newer medications like Mounjaro and Wegovy sit entirely outside these schemes for now — private prescription only.
The 80,000-person question
Around 1.2 million people in Ireland are classified as obese — roughly a quarter of the population. The HSE's national clinical lead for obesity, Professor Donal O'Shea, has estimated that if the injections are approved for State funding, around 80,000 people would be likely to avail of them.
What would that funding look like? Two routes: medical card holders would receive the medication free (standard prescription charges aside), and everyone else could claim it under the Drug Payment Scheme, which caps a household's total monthly medicine spend at €80.
For context: for most households that would cap the monthly outlay at €80 — the scheme's ceiling for all approved medicines combined — which is exactly why the State is negotiating so hard on price before making any decision.
Why the watchdog first said no
In late 2025, the National Centre for Pharmacoeconomics (NCPE) — the body that assesses whether medicines are worth their price to the State — concluded that Mounjaro was "not value for money" at its current price.
The numbers explain why. The NCPE estimated that adding Mounjaro to the reimbursement list could cost the Exchequer anywhere from €1.44 billion to €5.23 billion over five years, depending on how strictly eligibility was drawn.
The June 2026 turn: a "significant price reduction"
Then the story shifted. In June 2026, Professor Michael Barry, who leads the NCPE, told reporters: "My understanding is that a significant price reduction has been offered. I suspect we will be saying that the drug is cost-effective or very close to it."
With the reduced price, the projected five-year cost falls to an estimated €2–3 billion. Eli Lilly, for its part, says it is "working with the Health Service Executive to explore solutions that enable patient access in Ireland."
No date for a final decision has been announced. The remaining steps — Drugs Group consideration and sign-off by the HSE's senior leadership — have no fixed timeline, and no decision date has been signalled.
Who would qualify if the HSE says yes?
Nothing is decided yet, but the strongest signal comes from Professor O'Shea: "It's likely to come in somewhere quite along the lines of its availability in the UK, which is for people with a BMI over 35, plus complications."
On those signals, State funding would be unlikely to cover everyone currently paying privately. If your BMI is between 27 and 35, or you have a higher BMI without a diagnosed weight-related condition, the expectation is that you would remain outside the State scheme — as is the case in the UK's phased NHS rollout.
See how the claim works →What Mounjaro costs in Ireland right now
Privately, reported prices for Mounjaro in Ireland range from roughly €275 to €595 per month depending on the dose and provider. With Slimbr, all-in monthly pricing — doctor, medication and app support together — starts from €253 per month at the 2.5 mg starting dose.
We've published a full comparison of Irish providers — Slimbr vs myBMI, Inish Pharmacy, ZAVA and BeyondBMI — in our Mounjaro prices in Ireland guide. For the bigger picture on the medication itself, see our complete Mounjaro Ireland guide.
Two ways to cut the cost today (that most people miss)
While the HSE decision is pending, two supports already exist. First, some Irish health insurance plans refund up to 75% of the cost of GP or consultation visits — which can include the doctor side of a medical weight-loss programme, depending on your plan.
Second, tax relief: you can claim 20% back on qualifying medical expenses — including doctor fees and prescribed medication — through Revenue's Med 1 process. We've broken down exactly how both work in our guide to insurance refunds and tax relief on weight-loss treatment in Ireland.
What starting with a doctor looks like
Whether or not State funding arrives, medical weight loss in Ireland remains a prescription-only, doctor-led process. With Slimbr, it works like this:
What progress typically looks like
Everyone's response is individual, and a doctor will set expectations for your situation — but supervised treatment tends to follow a recognisable arc:
Should you wait for HSE funding?
That's a personal decision — and an honest article should say so. What the facts support: there is no announced date for a decision, approval is not guaranteed, and the expected criteria (BMI over 35 plus complications) would leave many people outside the scheme even if it's approved.
If you'd likely fall outside those criteria, the State decision may change little for you either way. If you'd likely fall inside them, the choice is between waiting an unknown number of months and starting privately now — a question worth putting to a doctor rather than a headline. An eligibility check takes about two minutes and costs nothing.
Mounjaro and the HSE: FAQs
Is Mounjaro free with a medical card in Ireland?
No. As of July 2026, Mounjaro is not reimbursed by the HSE for weight management, so medical card holders pay privately like everyone else. A reimbursement application is under active consideration, with price negotiations ongoing.
Is Mounjaro covered by the Drug Payment Scheme?
Not currently. If the HSE approves reimbursement, Mounjaro would fall under the scheme's €80 monthly household cap — but no approval has been granted and no decision date has been announced.
Is Wegovy covered by the HSE?
No. Wegovy (semaglutide) is also awaiting a reimbursement decision — Novo Nordisk applied in March 2025. Like Mounjaro, it is private-prescription only in Ireland today.
What weight-loss injection does the HSE cover?
Only Saxenda (liraglutide), under a strict Managed Access Protocol: broadly a BMI of 35 or higher plus prediabetes and high cardiovascular risk, with continued funding conditional on losing at least 5% of body weight in the first 12 weeks at the full dose.
When will the HSE decide on Mounjaro?
No date has been announced. As of June 2026, the NCPE's assessment is complete, a significant price reduction has been offered, and the file moves next to the HSE Drugs Group and then senior leadership for a final decision.
How much does Mounjaro cost in Ireland while it's not covered?
Reported private prices range from about €275 to €595 per month depending on dose and provider. Slimbr's all-in pricing (doctor + medication + app) starts from €253 per month at the starting dose — see our full price comparison for every dose.
